Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin: A double-blind, randomized, controlled trial

Annals of Internal Medicine

Volumn 126, Issue 9, 1997, Pages 697-703

  Khan, Wasif Ali ^b   Seas, Carlos ^c   Dhar, Ujjwal ^b   Salam, Mohammed Abdus ^b   Bennish, Michael L ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^c INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; FECES CULTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SHIGELLOSIS; TREATMENT OUTCOME;

EID: 0030933196     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-9-199705010-00004     Document Type: Article

References (39)

1. Bennish ML, Wojtyniak BJ. Mortality due to shigellosis: community and hospital data. Rev Infect Dis. 1991;13(Suppl 14):S245-51.
2. Keusch GT, Bennish ML. Shigellosis. In: Evans AS, Brachman PS, eds. Bacterial Infections of Humans. Epidemiology and Control. New York: Plenum; 1991:593-620.
3. Bennish ML, Levy S. Antimicrobial resistance of enteric pathogens. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, eds. Infections of the Gastrointestinal Tract. New York: Raven Pr; 1995:1499-523.
4. Bennish ML, Salam MA, Hossain MA, Myaux J, Khan EH, Chakraborty J, et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis. 1992;14:1055-66.
5. Ries AA, Wells JG, Olivola D, Ntakibirora M, Nyandwi S, Ntibakivayo M, et al. Epidemic Shigella dysenteriae Type 1 in Burundi: panresistance and implications for prevention. J Infect Dis. 1994;169:1035-41.
6. Salam MA, Bennish ML. Antimicrobial therapy for shigellosis. Rev Infect Dis. 1991;13(Suppl 4):S332-41.
7. Salam MA, Bennish ML. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr. 1988;113:901-7.
8. Bennish ML, Salam MA, Haider R, Barza M. Therapy of shigellosis II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis. 1990;162:711-6.
9. Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis: III. Comparison of one-or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med. 1992;117:727-34.
10. Salam MA, Seas C, Khan WA, Bennish ML. Treatment of shigellosis: IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med. 1995;123:505-8.
11. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994? Goma Epidemiology Group. Lancet. 1995;345:339-44.
12. Kabir I, Rahaman MM, Ahmed SM, Akhter SQ, Butler T. Comparative efficacies of pivmecillinam and ampicillin in acute shigellosis. Antimicrob Agents Chemother. 1984;25:643-5.
13. Rogerie F, Ott D, Vandepitte J, Verbist L, Lemmens P, Habiyaremye I. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults. Antimicrob Agents Chemother. 1986;29:883-6
14. De Mol P, Mets T, Lagasse R, Vandepitte J, Mutwewingabo A, Butzler JP. Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid. J Antimicrob Chemother. 1987;19:695-8.
15. Gotuzzo E, Oberhelman RA, Maguiña C, Berry SJ, Yi A, Guzman M, et al. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults. Antimicrob Agents Chemother. 1989;33:1101-4.
16. Bhattacharya SK, Bhattacharya MK, Dutta P, Sen D, Rasaily R, Moitra A, et al. Randomized clinical trial of norfloxacin for shigellosis. Am J Trop Med Hyg. 1991;45:683-7.
17. Bassily S, Hyams KC, el-Masry NA, Farid Z, Cross E, Bourgeois AL, et al. Short-course norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt. Am J Trop Med Hyg. 1994;51:219-23.
18. Schaad UB, Salam MA, Aujard Y, Dagan R, Green SD, Peltola H, et al. Use of fluroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J. 1995;14:1-9.
19. Nelson JD, Haltalin KC. Comparative efficacy of cephalexin and ampicillin for shigellosis and other types of acute diarrhea in infants and children. Antimicrob Agents Chemother. 1975;7:415-20.
20. Orenstein WA, Ross L, Overturf GD, Wilkins J, Redfield DR, Underman A. Antibiotic treatment of acute shigellosis: failure of cefamandole compared with trimethoprim/sulfamethoxazole and ampicillin. Am J Med Sci. 1981;282:27-33.
21. Quintiliani R, Nightingale CH, Freeman CD. Pharmokinetic and pharmocodynamic considerations in antibiotic selection, with particular attention to oral cephalosporins. Infectious Diseases in Clinical Practice. 1994;3:1-7.
22. Jones K, Felmingham J, Ridgway G. In vitro activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens. Drugs Exp Clin Res. 1988;14:613-5.
23. Gordillo ME, Singh KV, Murray B. In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother. 1993;37:1203-5.
24. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother. 1990;34:1056-60.
25. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989;33:277-82.
26. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother. 1993:3 (Suppl E):39-50.
27. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother. 1993;31(Suppl E):111-7.
28. Mandell GL. Delivery of antibiotics by phagocytes. Clin Infect Dis. 1994;19:922-5.
29. Haltalin KC, Nelson JD, Hinton LV, Kusmiesz HT, Sladoje M. Comparison of orally absorbable and nonabsorbable antibiotics in shigellosis. A double-blind study with ampicillin and neomycin. J Pediatr. 1968;72:708-20.
30. Haltalin KC, Nelson JD. Failure of furazolidone therapy in shigellosis. Am J Dis Child. 1972;123:40-4.
31. Bellamy C. The state of the world's children 1997. Oxford, United Kingdom: Oxford Univ Pr; 1997:80.
32. Grob PR. Antibiotic prescribing practices and patient compliance in the community. Scand J Infect Dis Suppl. 1992;83:7-14.
33. Martin DH, Mroczkowski TF, Dalu ZA, McCarty J, Jones RB, Hopkins SJ, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydia urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med. 1992;327:921-5.
34. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 1993;342:453-6.
35. Tyndall MW, Agoki E, Plummer FA, Malisa W, Ndinya-Achola JO, Ronald AR. Single dose azithromycin for the treatment of chancroid: a randomized comparison with erythromycin. Sex Transm Dis. 1994;21:231-4.
36. Kuschner RA, Trofa AF, Thomas RJ, Hoge CW, Pitarangsi C, Amato S, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers in Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis. 1995;21:536-41.
37. Gilman RH, Spira W, Rabbani H, Ahmed W, Islam A, Rahaman MM. Single-dose ampicillin therapy for severe shigellosis in Bangladesh. J Infect Dis. 1981;143:164-9.
38. Glass RI, Stoll BJ, Huq MI, Struelens MJ, Blaser M, Kibriya AK. Epidemiology and clinical features of endemic Campylobacter jejuni infection in Bangladesh. J Infect Dis. 1983;148:292-6.
39. Murphy GS Jr, Echeverria P, Jackson LR, Arness MK, LeBron C, Pitarangsi C. Ciprofloxacin-and azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin Infect Dis. 1996:22:868-9.